<DOC>
	<DOCNO>NCT02879110</DOCNO>
	<brief_summary>In propose study , investigator evaluate efficacy , safety relate mechanism sulforaphane treatment autism spectrum disorder ( ASD ) . The study recruit 120 ASD patient , patient randomize sulforaphane group placebo group ( 60 patient per arm ) 12 week clinic trial . Clinical efficacy safety assessment do screen/baseline , 4 week , 8 week 12 week . The specific aim compare sulforaphane versus placebo : 1 ) clinical core symptom ; 2 ) behavioral problem adaptive behavior . Biological sample also collect , store research relate mechanism .</brief_summary>
	<brief_title>A 12-weeks Study Evaluate Sulforaphane Treatment Autism Spectrum Disorder</brief_title>
	<detailed_description>In propose study , investigator evaluate efficacy , safety relate mechanism sulforaphane treatment autism spectrum disorder ( ASD ) . The study recruit 120 ASD patient , patient randomize sulforaphane group placebo group ( 60 patient per arm ) 12 week clinic trial . Clinical efficacy safety assessment do screen/baseline , 4 week , 8 week 12 week . The specific aim compare sulforaphane versus placebo : 1 ) clinical core symptom ; 2 ) behavioral problem adaptive behavior . The investigator hypothesize ( 1 ) sulforaphane superior placebo treatment clinical symptom patient ASD , measure Social Responsiveness Scale , Aberrant Behavior Checklist , Repetitive Behavior Scale - Revised Ohio State University Autism Clinical Global Impression ; ( 2 ) sulforaphane superior placebo treatment behavioral problem adaptive behavior patient ASD , measure Achenbach 's Child Behavior Checklist Adaptive Behavior Assessment System , Second Edition ; ( 3 ) Biological sample collect , store hypothesis sulforaphane may alter oxidative stress index inflammatory biomarkers , influence histone deacetylase inhibitor mechanism inflammatory mechanism et al may significantly correlate clinical improvement .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Sulforafan</mesh_term>
	<criteria>1 . Male age 10 15 year . 2 . Meet DSMV diagnostic criterion autism spectrum disorder , check Autism Diagnostic InterviewRevised ( ADIR ) Autism Diagnostic Observation Schedule ( ADOS ) . 1 . With severe physical disease ( i.e . congenital heart disease , thyroid disease , diseases severe abnormality liver kidney function , diseases abnormality vision hear et al . ) 2 . With severe central nervous system disease ( i.e . epilepsy et al ) . 3 . With specific genetic syndrome ( i.e . FragileX syndrome , Down 's syndrome et al . )</criteria>
	<gender>Male</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Sulforaphane</keyword>
	<keyword>clinic trial</keyword>
	<keyword>Autism Spectrum Disorder</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Mechanism</keyword>
</DOC>